Dynavax Technologies | DVAX - Frais De Vente Et D'Administration



Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.89B 325M 2025-12
Adma Biologics USD 20.19M 2.86M 2025-12
Agenus USD 10.56M 13.04M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD -0.18 0.07 2024-09
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
Pfizer USD 4.08B 894M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
TG Therapeutics USD 50.73M 12.64M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12